Company profile: Prolaio
1.1 - Company Overview
Company description
- Provider of prescriptive analytics-driven HealthTech solutions for continuous cardiac monitoring and risk assessment, including post-discharge heart failure and hypertrophic cardiomyopathy systems, AI-powered predictive analytics for care teams, remote monitoring for clinical studies, and a patient app for data collection, guidance, and reporting to support early intervention and reduce readmissions.
Products and services
- Predictive Analytics for Care Teams: Produces AI-driven prescriptive analytics using continuous patient data, enabling care teams to pinpoint early intervention and architect optimized care plans that reduce admissions and readmissions
- Continuous Patient Monitoring: Builds a continuous-monitoring platform using wearable devices and connected tools to stream real-time heart data and risk assessments to care teams for proactive intervention
- Heart Failure Transition Care: Engineers a post-discharge heart failure monitoring system using ECG patches, blood pressure cuffs, and scales to track health factors, assess risk, and help prevent readmissions.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Prolaio
Orange Grove Bio
HQ: United States
Website
- Description: Provider of a preclinical drug investment and development platform focused on reducing drug discovery costs and advancing therapies to clinical trials, offering direct sourcing and comprehensive diligence processes, seasoned operations teams, licensing via academic collaborations, and technologies such as Preservation Bio's platelet additive and Genexys BioMed's gene therapy platform.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Orange Grove Bio company profile →
PackGene
HQ: United States
Website
- Description: Provider of CRO/CDMO services for gene and cell therapy, specializing in AAV vectors, mRNA, plasmid DNA, and lentiviral solutions. Offerings include AAV vector design and construction; small- to large-scale AAV production up to GMP; π-Icosa serotype screening; Express Gene-to-AAV from synthesis to packaging; and on-demand gene editing mRNAs (e.g., Cas9). Supports discovery, preclinical, and trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PackGene company profile →
OctoPlus
HQ: The Netherlands
Website
- Description: Provider of specialty pharmaceutical expertise in the development of injectables. Based in a leading European bioscience park, the company is globally renowned and employs around 120 people representing over 20 nationalities.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OctoPlus company profile →
Qointa
HQ: Belgium
Website
- Description: Provider of a compliant, validated eHealth platform for device-agnostic patient monitoring and coaching, enabling direct randomization into adaptive clinical trials. Offers digital transformation and software validation solutions, quality and regulatory support (QMS and risk management), medical device software development, and electronic data integrity services.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Qointa company profile →
START Research
HQ: United States
Website
- Description: Provider of oncology and biotechnology research.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full START Research company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Prolaio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Prolaio
2.2 - Growth funds investing in similar companies to Prolaio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Prolaio
4.2 - Public trading comparable groups for Prolaio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →